Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 7.34
(6.22%)
USD 7.34
(6.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -44.6 Million USD | 20.11% |
| 2022 | -55.83 Million USD | -22.57% |
| 2021 | -45.55 Million USD | 59.07% |
| 2020 | -111.3 Million USD | -60.95% |
| 2019 | -69.15 Million USD | -24.22% |
| 2018 | -55.67 Million USD | -71.71% |
| 2017 | -32.42 Million USD | -62.12% |
| 2016 | -19.99 Million USD | -125.95% |
| 2015 | -8.85 Million USD | -248.39% |
| 2014 | -2.54 Million USD | -321.76% |
| 2013 | -602.35 Thousand USD | -67811.67% |
| 2012 | -886.96 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.89 Million USD | 14.0% |
| 2024 Q2 | -9.99 Million USD | -44.91% |
| 2023 Q1 | -18.68 Million USD | -70.75% |
| 2023 FY | -44.6 Million USD | 20.11% |
| 2023 Q4 | -8.02 Million USD | 20.21% |
| 2023 Q3 | -10.05 Million USD | -14.45% |
| 2023 Q2 | -8.78 Million USD | 53.0% |
| 2022 Q4 | -10.94 Million USD | -21.93% |
| 2022 Q3 | -8.97 Million USD | 63.89% |
| 2022 Q2 | -24.85 Million USD | -124.27% |
| 2022 Q1 | -11.08 Million USD | -8.02% |
| 2022 FY | -55.83 Million USD | -22.57% |
| 2021 Q1 | -16.06 Million USD | -86.55% |
| 2021 Q2 | -17.13 Million USD | -6.68% |
| 2021 Q3 | -2.17 Million USD | 87.3% |
| 2021 FY | -45.55 Million USD | 59.07% |
| 2021 Q4 | -10.26 Million USD | -371.51% |
| 2020 Q3 | -34.89 Million USD | 8.42% |
| 2020 Q2 | -38.1 Million USD | -28.49% |
| 2020 Q1 | -29.65 Million USD | -11.57% |
| 2020 FY | -111.3 Million USD | -60.95% |
| 2020 Q4 | -8.61 Million USD | 75.32% |
| 2019 Q3 | -20.79 Million USD | -1065.82% |
| 2019 FY | -69.15 Million USD | -24.22% |
| 2019 Q1 | -26.23 Million USD | -51.59% |
| 2019 Q4 | -26.58 Million USD | -27.85% |
| 2019 Q2 | 2.15 Million USD | 108.21% |
| 2018 Q2 | -12.06 Million USD | -3.2% |
| 2018 Q1 | -11.69 Million USD | -9.37% |
| 2018 FY | -55.67 Million USD | -71.71% |
| 2018 Q4 | -17.3 Million USD | -18.53% |
| 2018 Q3 | -14.6 Million USD | -20.98% |
| 2017 Q3 | -6.96 Million USD | 4.54% |
| 2017 FY | -32.42 Million USD | -62.12% |
| 2017 Q2 | -7.29 Million USD | 2.26% |
| 2017 Q4 | -10.69 Million USD | -53.52% |
| 2017 Q1 | -7.46 Million USD | 1.38% |
| 2016 Q3 | -5.34 Million USD | -27.63% |
| 2016 FY | -19.99 Million USD | -125.95% |
| 2016 Q4 | -7.57 Million USD | -41.59% |
| 2016 Q2 | -4.18 Million USD | -44.85% |
| 2016 Q1 | -2.89 Million USD | -15.75% |
| 2015 Q4 | -2.49 Million USD | -10.86% |
| 2015 Q2 | -2.56 Million USD | -66.86% |
| 2015 Q1 | -1.53 Million USD | -21.86% |
| 2015 FY | -8.85 Million USD | -248.39% |
| 2015 Q3 | -2.25 Million USD | 12.04% |
| 2014 Q4 | -1.26 Million USD | -91.06% |
| 2014 FY | -2.54 Million USD | -321.76% |
| 2014 Q3 | -659.62 Thousand USD | -30.72% |
| 2014 Q2 | -504.6 Thousand USD | -335.09% |
| 2014 Q1 | -115.97 Thousand USD | 59.99% |
| 2013 Q3 | -59.55 Thousand USD | 71.56% |
| 2013 Q1 | -43.54 USD | 0.0% |
| 2013 Q2 | -209.38 Thousand USD | -480844.51% |
| 2013 Q4 | -289.87 Thousand USD | -386.76% |
| 2013 FY | -602.35 Thousand USD | -67811.67% |
| 2012 FY | -886.96 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 83.847% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 62.364% |
| Editas Medicine, Inc. | -153.21 Million USD | 70.889% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 59.657% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 89.955% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.484% |
| uniQure N.V. | -308.47 Million USD | 85.541% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 49.59% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 87.332% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 70.575% |
| bluebird bio, Inc. | -211.91 Million USD | 78.952% |
| Blueprint Medicines Corporation | -506.98 Million USD | 91.202% |
| Adicet Bio, Inc. | -142.65 Million USD | 68.734% |
| Dynavax Technologies Corporation | -6.38 Million USD | -598.127% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 103.284% |
| Myriad Genetics, Inc. | -112 Million USD | 60.176% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 117.863% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 91.678% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 3489.31% |
| Verastem, Inc. | -87.36 Million USD | 48.947% |
| Waters Corporation | 642.23 Million USD | 106.945% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.232% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.744% |
| Biogen Inc. | 1.16 Billion USD | 103.841% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 48.072% |
| Perrigo Company plc | -12.7 Million USD | -251.207% |
| Imunon, Inc. | -19.51 Million USD | -128.559% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 78.684% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 105.655% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 17.688% |
| Geron Corporation | -184.12 Million USD | 75.776% |
| Illumina, Inc. | -1.16 Billion USD | 96.158% |
| Homology Medicines, Inc. | -53.74 Million USD | 17.006% |
| Nektar Therapeutics | -276.05 Million USD | 83.843% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -11.9% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 126.606% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 82.701% |
| Evolus, Inc. | -61.68 Million USD | 27.692% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.128% |
| FibroGen, Inc. | -284.23 Million USD | 84.307% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 103.597% |
| OPKO Health, Inc. | -188.86 Million USD | 76.383% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 89.868% |
| Exelixis, Inc. | 207.76 Million USD | 121.468% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 6.108% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 90.731% |
| Zoetis Inc. | 2.34 Billion USD | 101.903% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 81.356% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -5.698% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 87.823% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 142.023% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 115.84% |
| Insmed Incorporated | -749.56 Million USD | 94.049% |
| TG Therapeutics, Inc. | 12.67 Million USD | 451.983% |
| Incyte Corporation | 597.59 Million USD | 107.464% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 94.135% |